69 results
Page 3 of 4
8-K
EX-99.1
1ica6884
13 May 22
Adagio Therapeutics Reports First Quarter 2022 Financial Results
7:00am
10-K/A
g276 b7iq9
29 Apr 22
Annual report (amended)
4:43pm
PREC14A
0ajlk17n
26 Apr 22
Preliminary proxy with contested solicitation
8:48am
10-K
olthfuofvoiv9 5yx7
31 Mar 22
Annual report
8:18am
8-K
EX-99.1
hh0cg82ju7z p6pmilwy
30 Mar 22
Results of Operations and Financial Condition
7:40am
8-K
EX-99.1
pgo2crnpxz336rqb
23 Feb 22
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
5:07pm
8-K
EX-99.2
c4ikof0dwavparg2s
22 Feb 22
Adagio Therapeutics Announces CEO Succession Plan
7:57am
8-K
EX-99.1
c0645
13 Jan 22
Regulation FD Disclosure
8:01am
8-K
EX-99.1
6yor5v zr7bhzyn
14 Dec 21
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
9:10am
8-K
EX-99.1
1ido rb5v
29 Nov 21
Regulation FD Disclosure
8:23am
8-K
EX-99.1
1804ufa0mx8y 5wc4
22 Nov 21
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors
5:04pm
8-K
EX-99.1
jjckj9 ox1
15 Nov 21
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
8:08am
8-K
EX-99.1
3mcd77
19 Oct 21
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
4:03pm
8-K
EX-99.1
1ui9wiwrfupsmi nr2i4
29 Sep 21
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
4:41pm
10-Q
EX-10.5
i9tspruf
20 Sep 21
Quarterly report
4:17pm
10-Q
fmqflbkphonhzcesuxnx
20 Sep 21
Quarterly report
4:17pm
8-K
EX-99.1
vb9ygtw81nboai
20 Sep 21
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business
4:05pm
424B4
5erthmcvao5732
6 Aug 21
Prospectus supplement with pricing info
4:54pm